Singapore-based medical testing firm Mirxes joins Jiangsu Hengrui Pharmaceuticals in revitalised market’s listing surge.

Now, with tensions easing and the US$43.6 billion ($56.62 billion) raised in 2025 IPOs so far running just behind the same ...

SINGAPORE] Singapore biotech start-up Mirxes launched its initial public offering (IPO) in Hong Kong on Thursday (May 15) as ...

Hong Kong is calling for robotaxi operator Pony AI . The $6 billion Chinese company is exploring an offering in the city just ...

Alibaba reported a 93% YoY increase in operating income for the March 2025 quarter, driven by strong cloud revenue and sustained triple-digit growth in AI products. Total revenue rose 7% to RMB 236.5 ...

The underwriters on Hengrui Pharmaceutical Hong Kong listing are represented by Herbert Smith Freehills and Jingtian & ...

Jiangsu Hengrui Pharmaceuticals is planning to raise as much as US$1.27 billion via an initial public offering in Hong Kong, joining a wave of Chinese companies seeking to tap the city's market.

By Scott Murdoch (Reuters) -Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is aiming to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong listing, according to a ...

Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is seeking to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong listing, according to a regulatory filing made on Thursday.

Jiangsu Hengrui Pharmaceuticals Co. has started taking investor orders for a Hong Kong listing that could raise as much as ...

Charming Medical, which provides therapies and products inspired by traditional Chinese medicine, filed for an initial public offering of 1.6 million shares. The company said in a filing with the ...